Affinage

EIF5A2

Eukaryotic translation initiation factor 5A-2 · UniProt Q9GZV4

Length
153 aa
Mass
16.8 kDa
Annotated
2026-06-09
69 papers in source corpus 24 papers cited in narrative 24 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 5/5 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

EIF5A2 encodes a hypusine-modified isoform of the eukaryotic translation factor eIF5A whose activity, like that of eIF5A1, depends on the spermidine-derived hypusine modification at lysine-50; CRISPR K50R knock-in mice confirm hypusination is required for activation and reveal that its loss reshapes the cellular metabolite landscape (PMID:11161802, PMID:36848144). Its synthesis is gated translationally: elements in the 5'-UTR render its mRNA inefficiently translated (PMID:16519677), and polyamines relieve this block by inhibiting miR-6514-5p, which otherwise represses eIF5A2 translation at the 5'-UTR (PMID:40617352). Functionally, eIF5A2 acts as a translation elongation factor that selectively promotes synthesis of proline-rich proteins such as MTFR1, and as an oncogene it drives anchorage-independent growth, tumor formation, invasion, and epithelial-mesenchymal transition (EMT) across multiple cancer types (PMID:15205331, PMID:41730614). Several of its pro-metastatic outputs converge on transcriptional programs—it stabilizes STAT3 to activate TGF-β1 transcription and downstream Smad2/3 signaling (PMID:24504366, PMID:32138807), enriches c-Myc on the MTA1 promoter to drive EMT (PMID:21813470), and engages an E2F1/KLF4 axis for cancer stemness (PMID:33726845)—and it amplifies angiogenesis through p38/JNK/c-Jun-driven MMP-2 and a bidirectional loop with HIF1α (PMID:25071013, PMID:24561231). eIF5A2 protein levels are set by competing ubiquitin machinery: the E3 ligase HERC3 binds via its RCC1 domain and catalyzes K27/K48-linked ubiquitination at K47/K67/K85/K121 for proteasomal degradation (PMID:35064108), TRIM71 likewise destabilizes the protein (PMID:39579322), while the deubiquitinase ATXN3 stabilizes it (PMID:34428509). Loss of eIF5A2 activity—via gene hypermethylation or hypusination inhibition—sensitizes AML cells to venetoclax (PMID:41606290).

Mechanistic history

Synthesis pass · year-by-year structured walk · 10 steps
  1. 2001 Medium

    Established that EIF5A2 is a distinct eIF5A isoform predicted to carry the hypusine modification essential for eIF5A activity, defining the protein's basic identity.

    Evidence Molecular cloning and gene-structure/sequence analysis of the 153-residue protein

    PMID:11161802

    Open questions at the time
    • Hypusination of eIF5A2 inferred from sequence identity, not directly demonstrated here
    • No functional or cellular role established
  2. 2004 High

    Resolved whether EIF5A2 amplification has biological consequence by showing it is a tumorigenic oncogene whose suppression limits cancer cell growth.

    Evidence Soft-agar colony formation, nude-mouse xenograft, antisense knockdown in amplified ovarian cancer cells

    PMID:15205331

    Open questions at the time
    • Molecular mechanism of transformation not defined
    • No translation-factor activity tested
  3. 2006 Medium

    Addressed how EIF5A2 expression is constrained by demonstrating hypusination occurs but mRNA translation is inefficient due to UTR elements, while the protein is stable once made.

    Evidence Polysome fractionation, heterologous expression, pulse-chase stability assay

    PMID:16519677

    Open questions at the time
    • Specific UTR element and trans-acting factor not identified
    • Single lab
  4. 2011 High

    Connected EIF5A2 to metastasis mechanistically by showing it drives EMT through c-Myc-dependent MTA1 induction, and organismally that its overexpression accelerates aging via p19/p53 destabilization and chromosomal instability.

    Evidence Reciprocal gain/loss-of-function, ChIP, MTA1 epistasis rescue, in vivo metastasis; separate transgenic mouse with cytogenetics

    PMID:21612665 PMID:21813470

    Open questions at the time
    • Link between translation-factor activity and transcriptional outputs unexplained
    • How eIF5A2 enriches c-Myc on the promoter unclear
  5. 2014 High

    Mapped multiple downstream effector pathways: EIF5A2 stabilizes STAT3 to transcribe TGF-β1 (EMT), activates p38/JNK/c-Jun to raise MMP-2 (angiogenesis), and forms a bidirectional amplification loop with HIF1α.

    Evidence ChIP, nuclear fractionation, luciferase reporters, knockdown/overexpression, xenograft vessel and perfusion assays

    PMID:24504366 PMID:24561231 PMID:25071013

    Open questions at the time
    • Whether these pathways are direct consequences of eIF5A2 translation activity not shown
    • Convergence vs. context-specificity of pathways unresolved
  6. 2021 Medium

    Extended the oncogenic program to stemness (E2F1/KLF4), hormone-dependent regulation (AR induces EIF5A2), and established ATXN3 as a deubiquitinase that stabilizes eIF5A2.

    Evidence CRISPR KO/overexpression, RNA-seq, sphere assays, epistasis rescue, DHT/bicalutamide treatment, Co-IP and ubiquitination assays

    PMID:33726845 PMID:33827661 PMID:34428509 PMID:34864817

    Open questions at the time
    • DUB site specificity on eIF5A2 not mapped
    • AR regulation mechanism (direct vs indirect) not defined
  7. 2022 High

    Defined the principal degradative control of eIF5A2 by identifying HERC3 as the E3 ligase that ubiquitinates specific lysines for proteasomal turnover, and added AGR2 as a downstream effector.

    Evidence Co-IP, GST pulldown, linkage-specific ubiquitination, site-directed mutagenesis, in vitro/in vivo ubiquitination; separate Co-IP and epistasis for AGR2

    PMID:35064108 PMID:35640539

    Open questions at the time
    • What signals control HERC3 vs ATXN3 balance unknown
    • AGR2 interaction validated by single Co-IP
  8. 2023 High

    Validated hypusination at K50 as essential for eIF5A2 activation in vivo and revealed metabolic consequences of its loss.

    Evidence CRISPR K50R knock-in mouse, anti-hypusine Western blot, fibroblast metabolomics

    PMID:36848144

    Open questions at the time
    • Mechanistic link between hypusine loss and the metabolite changes not established
    • Translation targets responsible not identified
  9. 2025 High

    Established the translational regulatory circuit and demonstrated eIF5A2 has distinct (non-redundant with eIF5A1) protein-synthesis targets relevant to cancer growth.

    Evidence Polyamine/miR-6514-5p analysis, 5'-UTR reporters, isoform-specific siRNA, quantitative proteomics

    PMID:40617352

    Open questions at the time
    • Full repertoire of eIF5A2-specific translated mRNAs incomplete
    • How the distinct targets produce the oncogenic phenotype unresolved
  10. 2026 Medium

    Linked eIF5A2 elongation activity to a defined motif preference (proline-rich proteins, e.g. MTFR1) and to therapeutic vulnerabilities, including venetoclax sensitization upon loss of activity and small-molecule elongation inhibitors.

    Evidence MTFR1 reporter HTS, siRNA, invasion assays; AML methylation and hypusination-inhibition venetoclax assays

    PMID:41606290 PMID:41730614

    Open questions at the time
    • Mechanism connecting elongation inhibition to venetoclax sensitivity not defined
    • Inhibitor specificity for eIF5A2 vs eIF5A1 not established

Open questions

Synthesis pass · forward-looking unresolved questions
  • How eIF5A2's core function as a hypusine-dependent elongation factor for specific (proline-rich) mRNAs mechanistically generates its diverse transcriptional and signaling outputs—and which translated targets are responsible for each oncogenic pathway—remains unresolved.
  • No structural model of eIF5A2-ribosome engagement in the corpus
  • Causal chain from elongation activity to STAT3/c-Myc/HIF1α outputs not demonstrated
  • Tissue-specific determinants of which pathway dominates unknown

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0045182 translation regulator activity 4 GO:0140110 transcription regulator activity 3
Localization
GO:0005829 cytosol 1
Pathway
R-HSA-162582 Signal Transduction 5 R-HSA-1643685 Disease 3 R-HSA-392499 Metabolism of proteins 3
Partners
AGR2ATXN3HERC3HIF1ASTAT3TRIM71

Evidence

Reading pass · 24 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2001 EIF5A2 encodes a 153-amino-acid eIF5A isoform that, like eIF5A1, receives the unique spermidine-derived post-translational modification hypusine, which is necessary for eIF5A biochemical activity. The gene spans 17 kb with 5 exons and produces two mRNAs via differential polyadenylation sharing the same coding sequence. Molecular cloning, sequence characterization, gene structure analysis Genomics Medium 11161802
2006 eIF5A-2 precursor protein is modified by hypusination comparably to eIF5A-1 in UACC-1598 cells. eIF5A-2 mRNA is inefficiently translated relative to eIF5A-1, with only a small fraction associating with polysomes; the elements causing inefficient translation reside outside the open reading frame (within the UTRs). Both isoforms are similarly stable once synthesized. Sucrose gradient polysome fractionation, mammalian expression vectors in 293T cells, Western blot, pulse-chase stability assay The FEBS journal Medium 16519677
2004 EIF5A2 has tumorigenic activity: ectopic expression enables anchorage-independent growth in soft agar and tumor formation in nude mice. Antisense DNA against eIF5A2 inhibits cell growth in an ovarian cancer cell line (UACC-1598) that harbors EIF5A2 amplification as double minutes. Soft agar colony formation, nude mouse xenograft, antisense oligonucleotide knockdown, copy-number reduction Cancer research High 15205331
2011 EIF5A2 overexpression promotes colorectal carcinoma cell motility, invasion, and epithelial-mesenchymal transition (EMT) in vitro and metastasis in vivo. Mechanistically, EIF5A2 upregulates MTA1 via enhanced enrichment of c-Myc on the MTA1 promoter; MTA1 knockdown eliminates EIF5A2-driven migration, invasion, and EMT. Ectopic overexpression and siRNA knockdown in CRC cell lines, in vitro invasion/migration assays, in vivo metastasis model, ChIP assay for c-Myc on MTA1 promoter, epistasis by MTA1 siRNA rescue Gut High 21813470
2011 Transgenic overexpression of eIF5A2 in mice accelerates organismal aging (decreased growth, shortened lifespan, kyphosis, osteoporosis, impaired wound healing) by increasing chromosomal instability. Mechanistically, eIF5A2 represses p19 (ARF), thereby destabilizing p53 in mouse embryo fibroblasts, leading to accumulation of mitotic errors (misaligned/lagging chromosomes, anaphase bridges, micronuclei) and increased aneuploidy. eIF5A2 transgenic mouse model, MEF isolation, immunohistochemistry, Western blot (p19, p53), cytogenetic analysis of mitotic figures, flow cytometry for aneuploidy BMC cancer Medium 21612665
2013 EIF5A2 is a downstream target of phosphorylated Akt (PI3K/Akt pathway) in melanoma cells. EIF5A2 overexpression increases, and knockdown decreases, melanoma cell invasion and MMP-2 activity. Tissue microarray, EIF5A2 overexpression/knockdown in melanoma cell lines, invasion assay, zymography for MMP-2 activity, correlation with Akt phosphorylation status British journal of cancer Medium 24178756
2014 EIF5A2 activates TGF-β1 expression to induce EMT in bladder cancer cells. Specifically, EIF5A2 stabilizes STAT3 and stimulates its nuclear localization, resulting in increased STAT3 binding to the TGF-β1 promoter and enhanced TGF-β1 transcription. EIF5A2 overexpression and knockdown in bladder cancer cell lines, ChIP assay for STAT3 on TGF-β1 promoter, Western blot for STAT3 nuclear localization, EMT marker analysis, in vivo metastasis model British journal of cancer High 24504366
2014 EIF5A2 ablation in hepatocellular carcinoma inhibits tumor angiogenesis by reducing MMP-2 expression. EIF5A2 silencing increases vessel wall continuity, blood perfusion, and tumor oxygenation. EIF5A2 enhances MMP-2 activity via activation of the p38 MAPK and JNK/c-Jun signaling pathways. EIF5A2 knockdown in HCC cell lines and xenografts, fluorescent immunostaining, transmission electron microscopy, tumor perfusion assays, tumor hypoxia assays, Western blot for p38/JNK/c-Jun Oncotarget High 25071013
2014 EIF5A2 is induced by hypoxia (4–8 fold) in esophageal squamous cell carcinoma cells, and there is bidirectional regulation between EIF5A2 and HIF1α (each upregulates the other). EIF5A2 promotes HIF1α expression and downstream VEGF, contributing to angiogenesis and EMT. Luciferase reporter assay, chromatin immunoprecipitation (HIF1α on EIF5A2 promoter), quantitative RT-PCR, EIF5A2 overexpression/knockdown, xenograft tumors with vessel counting Gastroenterology High 24561231
2022 HERC3 E3 ubiquitin ligase directly interacts with EIF5A2 via its RCC1 domain, promotes K27- and K48-linked ubiquitination of EIF5A2 via its HECT domain, and targets EIF5A2 for proteasomal degradation. The ubiquitination sites on EIF5A2 were identified as K47, K67, K85, and K121. HERC3-mediated degradation of EIF5A2 inhibits EMT through the TGF-β/Smad2/3 pathway. Co-immunoprecipitation, GST pulldown, immunoprecipitation with ubiquitin linkage-specific antibodies, site-directed mutagenesis of EIF5A2 lysine residues, in vivo and in vitro ubiquitination assays Cell death & disease High 35064108
2021 EIF5A2 promotes EMT in ovarian cancer cells via activation of the TGFβ pathway. CRISPR/Cas9 knockout of EIF5A2 inhibits EMT, cell migration, invasion, and ovarian tumor growth and metastasis in orthotopic mouse models, while EIF5A2 overexpression promotes these phenotypes. Lentiviral CRISPR/Cas9 nickase knockout, lentiviral overexpression, in vitro migration/invasion assays, orthotopic ovarian cancer mouse model, Western blot for TGFβ pathway and EMT markers Cell & bioscience High 33827661
2021 EIF5A2 promotes stemness in ovarian cancer cells via the E2F1/KLF4 pathway. EIF5A2 knockdown reduces KLF4 expression through E2F1, and KLF4 overexpression can partially rescue stem-like properties abolished by EIF5A2 knockdown; the transcription factor E2F1 directly binds the KLF4 promoter. EIF5A2 knockdown (siRNA), RNA-seq, sphere-forming assays, western blot, flow cytometry, in vivo xenograft, E2F1 epistasis rescue experiments Stem cell research & therapy Medium 33726845
2021 Androgen receptor (AR) positively regulates EIF5A2 expression in androgen-dependent prostate cancer cells in response to DHT stimulation; anti-androgen bicalutamide reduces EIF5A2 expression. EIF5A2 knockdown eliminates DHT-induced EMT and invasion/migration. DHT stimulation and bicalutamide treatment of AR-positive/negative PCa cell lines, EIF5A2 knockdown, Western blot for EMT markers, in vivo lung metastasis assay with luciferase imaging Cell death discovery Medium 34864817
2021 The deubiquitinating enzyme ATXN3 directly binds EIF5A2 and stabilizes it by reducing its ubiquitination and proteasomal degradation; ATXN3 promotes EIF5A2-dependent proliferation and metastasis in anaplastic thyroid carcinoma cells. Co-immunoprecipitation, ubiquitination assay, gain/loss-of-function experiments, Western blot for EIF5A2 stability Molecular and cellular endocrinology Medium 34428509
2022 EIF5A2 interacts with AGR2 (anterior gradient 2) by co-immunoprecipitation in cervical cancer cells; AGR2 overexpression reverses the reduction in proliferation, migration, invasion, and cisplatin sensitivity caused by EIF5A2 knockdown, placing AGR2 downstream of EIF5A2. Co-immunoprecipitation, EIF5A2 knockdown, AGR2 overexpression epistasis rescue, proliferation/apoptosis/invasion assays Pharmacology Medium 35640539
2023 EIF5A2 promotes doxorubicin resistance in bladder cancer cells through the TGF-β signaling pathway; EIF5A2 upregulates TGF-β1, p-Smad2, and p-Smad3, and a TGF-β pathway activator (SRI-011381) reverses the sensitizing effect of EIF5A2 knockdown. Doxorubicin-resistant cell line construction, EIF5A2 siRNA knockdown, TGF-β pathway activator rescue, Western blot for TGF-β1/p-Smad2/3, CCK-8 viability assay Discovery medicine Medium 38058082
2023 EIF5A2 K50R knock-in mice (CRISPR-Cas9) preventing hypusination at lysine-50 confirm that hypusine formation is required for eIF5A2 activation; metabolomic analysis of primary mouse dermal fibroblasts from eif5a2-K50R/K50R mice reveals significant alterations in the metabolite landscape, including increased tryptophan, kynurenine, pyridoxine, NAD, riboflavin, FAD, pantothenate, and CoA levels compared to controls. CRISPR-Cas9 K50R knock-in mouse model, Western blot with anti-hypusine antibody, metabolomics of primary dermal fibroblasts Biology open High 36848144
2024 TRIM71 (tripartite motif containing 71) directly interacts with eIF5A2 (verified by co-immunoprecipitation) and decreases eIF5A2 protein stability without affecting its mRNA level; TRIM71 overexpression inhibits LSCC tumor growth, and this anti-tumor effect is abolished by eIF5A2 overexpression. Co-immunoprecipitation, cycloheximide chase assay (protein half-life), quantitative PCR (mRNA level unchanged), overexpression epistasis rescue, in vivo xenograft Applied biochemistry and biotechnology Medium 39579322
2025 EIF5A2 protein synthesis is regulated at the translational level by polyamines: miR-6514-5p binds the 5'-UTR of eIF5A2 mRNA and negatively regulates its translation; polyamines inhibit miR-6514-5p function, thereby facilitating eIF5A2 synthesis. Proteomic analysis shows eIF5A2 and eIF5A1 regulate distinct sets of proteins, and eIF5A2 (not eIF5A1) is important for cancer cell growth. eIF5A2 silencing differentially regulates specific ribosomal proteins (RPS27A, RPL36A, RPL22L1) associated with cancer malignancy. Polyamine treatment with miR-6514-5p analysis, 5'-UTR reporter assays, eIF5A1/eIF5A2-specific siRNA knockdown, quantitative proteomics, cell proliferation assays The Journal of biological chemistry High 40617352
2026 eIF5A2-dependent translation elongation specifically regulates the synthesis of proteins with proline-rich motifs, including MTFR1 (mitochondrial fission regulator 1). A high-throughput screen identified orlistat and andrographolide as inhibitors of eIF5A2-dependent translation elongation. eIF5A2 silencing and these inhibitors suppress heparanase 1 (but not MMP-2 or MMP-9) expression and inhibit cancer cell invasion. MTFR1-luciferase reporter high-throughput screen (1744 compounds), eIF5A2 siRNA knockdown, invasion assays, Western blot for heparanase 1/MMP2/MMP9 Biological & pharmaceutical bulletin Medium 41730614
2026 Loss of EIF5A2 activity—either through gene hypermethylation (epigenetic silencing) or pharmacological inhibition of its hypusine post-translational modification—induces venetoclax sensitivity in AML cells. Gene methylation analysis, pharmacological inhibition of hypusination, venetoclax sensitivity assays in AML cell lines British journal of haematology Medium 41606290
2019 miR-9 enhances chemosensitivity to daunorubicin in AML cells by targeting EIF5A2; EIF5A2 knockdown reduces MCL-1 expression, and the sensitizing effect of miR-9 requires downregulation of EIF5A2, placing MCL-1 downstream of EIF5A2 in this context. miR-9 overexpression/knockdown, EIF5A2 siRNA, Western blot for MCL-1, cell viability and apoptosis assays, epistasis by EIF5A2 rescue of miR-9 effects International journal of biological sciences Medium 30745844
2020 EIF5A2 controls EMT and chemoresistance in thyroid and other cancers via the TGF-β/Smad2/3 signaling pathway. In anaplastic thyroid carcinoma, EIF5A2 overexpression upregulates p-Smad2/3, and TGF-β pathway inhibition (SB431542 or Smad3 siRNA) blocks the growth-promoting effect of EIF5A2 overexpression. shRNA knockdown, ectopic overexpression, recombinant TGF-β1 rescue, SB431542 pharmacological inhibition, Smad3 siRNA, Western blot for p-Smad2/3, in vitro and xenograft experiments Oncology research Medium 32138807
2022 EIF5A2 overexpression activates the PI3K/AKT/mTOR signaling pathway and upregulates Cyclin D1, Cyclin D3, MMP2, and MMP9 to promote intrahepatic cholangiocarcinoma cell proliferation, migration, and invasion. EIF5A2 overexpression/knockdown, Western blot for PI3K/AKT/mTOR components and cell cycle proteins, proliferation (CCK-8, EdU), invasion/migration (Transwell, scratch) assays Clinics and research in hepatology and gastroenterology Low 35792239

Source papers

Stage 0 corpus · 69 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2011 Overexpression of EIF5A2 promotes colorectal carcinoma cell aggressiveness by upregulating MTA1 through C-myc to induce epithelial-mesenchymaltransition. Gut 147 21813470
2001 Human eIF5A2 on chromosome 3q25-q27 is a phylogenetically conserved vertebrate variant of eukaryotic translation initiation factor 5A with tissue-specific expression. Genomics 117 11161802
2004 Oncogenic role of eIF-5A2 in the development of ovarian cancer. Cancer research 105 15205331
2014 Increased expression of EIF5A2, via hypoxia or gene amplification, contributes to metastasis and angiogenesis of esophageal squamous cell carcinoma. Gastroenterology 92 24561231
2016 MiRNA-203 suppresses cell proliferation, migration and invasion in colorectal cancer via targeting of EIF5A2. Scientific reports 91 27376958
2006 Differential expression of eIF5A-1 and eIF5A-2 in human cancer cells. The FEBS journal 88 16519677
2008 Expression and amplification of eIF-5A2 in human epithelial ovarian tumors and overexpression of EIF-5A2 is a new independent predictor of outcome in patients with ovarian carcinoma. Gynecologic oncology 70 19054548
2007 Overexpression of EIF-5A2 is associated with metastasis of human colorectal carcinoma. Human pathology 63 17949776
2014 EIF5A2 predicts outcome in localised invasive bladder cancer and promotes bladder cancer cell aggressiveness in vitro and in vivo. British journal of cancer 55 24504366
2015 Eukaryotic translation initiation factor 5A2 (eIF5A2) regulates chemoresistance in colorectal cancer through epithelial mesenchymal transition. Cancer cell international 49 26581310
2015 MiR-30b suppresses tumor migration and invasion by targeting EIF5A2 in gastric cancer. World journal of gastroenterology 43 26309359
2020 Long non-coding RNA LINC00520 promotes the proliferation and metastasis of malignant melanoma by inducing the miR-125b-5p/EIF5A2 axis. Journal of experimental & clinical cancer research : CR 42 32466797
2013 Role of EIF5A2, a downstream target of Akt, in promoting melanoma cell invasion. British journal of cancer 41 24178756
2020 Interactions Between lncRNA TUG1 and miR-9-5p Modulate the Resistance of Breast Cancer Cells to Doxorubicin by Regulating eIF5A2. OncoTargets and therapy 38 33380806
2009 Overexpression of EIF-5A2 is an independent predictor of outcome in patients of urothelial carcinoma of the bladder treated with radical cystectomy. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 38 19155439
2015 Stemness and chemotherapeutic drug resistance induced by EIF5A2 overexpression in esophageal squamous cell carcinoma. Oncotarget 36 26317793
2015 Mg(II)-Catechin nanoparticles delivering siRNA targeting EIF5A2 inhibit bladder cancer cell growth in vitro and in vivo. Biomaterials 36 26731576
2020 LncRNA FTX Contributes to the Progression of Colorectal Cancer Through Regulating miR-192-5p/EIF5A2 Axis. OncoTargets and therapy 33 32280242
2017 MicroRNA-599 inhibits metastasis and epithelial-mesenchymal transition via targeting EIF5A2 in gastric cancer. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 33 29091897
2021 Androgen receptor regulates eIF5A2 expression and promotes prostate cancer metastasis via EMT. Cell death discovery 32 34864817
2019 miR-9 Enhances the Chemosensitivity of AML Cells to Daunorubicin by Targeting the EIF5A2/MCL-1 Axis. International journal of biological sciences 31 30745844
2019 MicroRNA-33a-5p overexpression sensitizes triple-negative breast cancer to doxorubicin by inhibiting eIF5A2 and epithelial-mesenchymal transition. Oncology letters 31 31788073
2018 Downregulation of EIF5A2 by miR-221-3p inhibits cell proliferation, promotes cell cycle arrest and apoptosis in medulloblastoma cells. Bioscience, biotechnology, and biochemistry 30 30551723
2014 EIF5A2 is a novel chemoresistance gene in breast cancer. Breast cancer (Tokyo, Japan) 30 24638963
2009 Overexpression of EIF-5A2 predicts tumor recurrence and progression in pTa/pT1 urothelial carcinoma of the bladder. Cancer science 29 19298601
2022 HERC3 regulates epithelial-mesenchymal transition by directly ubiquitination degradation EIF5A2 and inhibits metastasis of colorectal cancer. Cell death & disease 28 35064108
2018 eIF5A2 regulates the resistance of gastric cancer cells to cisplatin via induction of EMT. American journal of translational research 28 30662669
2014 Ablation of EIF5A2 induces tumor vasculature remodeling and improves tumor response to chemotherapy via regulation of matrix metalloproteinase 2 expression. Oncotarget 28 25071013
2022 Long non-coding RNA HNF1A-AS1 induces 5-FU resistance of gastric cancer through miR-30b-5p/EIF5A2 pathway. Translational oncology 27 35092904
2018 MicroRNA-588 regulates invasion, migration and epithelial-mesenchymal transition via targeting EIF5A2 pathway in gastric cancer. Cancer management and research 27 30464616
2020 Overexpression of microRNA-9 enhances cisplatin sensitivity in hepatocellular carcinoma by regulating EIF5A2-mediated epithelial-mesenchymal transition. International journal of biological sciences 26 32071552
2017 GC7 enhances cisplatin sensitivity via STAT3 signaling pathway inhibition and eIF5A2 inactivation in mesenchymal phenotype oral cancer cells. Oncology reports 26 29286162
2020 Circ_0003998 enhances doxorubicin resistance in hepatocellular carcinoma by regulating miR-218-5p/EIF5A2 pathway. Diagnostic pathology 25 33308276
2021 EIF5A2 enhances stemness of epithelial ovarian cancer cells via a E2F1/KLF4 axis. Stem cell research & therapy 24 33726845
2021 EIF5A2 controls ovarian tumor growth and metastasis by promoting epithelial to mesenchymal transition via the TGFβ pathway. Cell & bioscience 23 33827661
2016 eIF5A2 is an alternative pathway for cell proliferation in cetuximab-treated epithelial hepatocellular carcinoma. American journal of translational research 21 27904670
2020 LncRNA GSEC promotes the proliferation, migration and invasion by sponging miR-588/ EIF5A2 axis in osteosarcoma. Biochemical and biophysical research communications 19 32868080
2019 Long Noncoding RNA TP73-AS1 Modulates Medulloblastoma Progression In Vitro And In Vivo By Sponging miR-494-3p And Targeting EIF5A2. OncoTargets and therapy 19 31819485
2018 Knockdown of EIF5A2 inhibits the malignant potential of non-small cell lung cancer cells. Oncology letters 18 29541224
2013 Down-regulation of eIF5A-2 prevents epithelial-mesenchymal transition in non-small-cell lung cancer cells. Journal of Zhejiang University. Science. B 18 23733422
2022 Genistein Restricts the Epithelial Mesenchymal Transformation (EMT) and Stemness of Hepatocellular Carcinoma via Upregulating miR-1275 to Inhibit the EIF5A2/PI3K/Akt Pathway. Biology 17 36290289
2021 The deubiquitinating enzyme ATXN3 promotes the progression of anaplastic thyroid carcinoma by stabilizing EIF5A2. Molecular and cellular endocrinology 16 34428509
2011 Overexpression of eIF-5A2 in mice causes accelerated organismal aging by increasing chromosome instability. BMC cancer 16 21612665
2020 Long non-coding RNA GAS6-AS1 acts as a ceRNA for microRNA-585, thereby increasing EIF5A2 expression and facilitating hepatocellular carcinoma oncogenicity. Cell cycle (Georgetown, Tex.) 15 32089066
2021 Circ_0058058 Knockdown Inhibits Acute Myeloid Leukemia Progression by Sponging miR-4319 to Regulate EIF5A2 Expression. Cancer biotherapy & radiopharmaceuticals 13 33470895
2020 EIF5A2 Is Highly Expressed in Anaplastic Thyroid Carcinoma and Is Associated With Tumor Growth by Modulating TGF- Signals. Oncology research 13 32138807
2019 Thermo-chemotherapy inhibits the proliferation and metastasis of gastric cancer cells via suppression of EIF5A2 expression. OncoTargets and therapy 10 31496731
2020 Targeting eIF5A2 inhibits prostate carcinogenesis, migration, invasion and metastasis in vitro and in vivo. Bioengineered 9 32522053
2023 EIF5A2 Promotes Doxorubicin Resistance in Bladder Cancer Cells through the TGF-β Signaling Pathway. Discovery medicine 8 38058082
2022 EIF5A2 promotes proliferation and invasion of intrahepatic cholangiocarcinoma cells. Clinics and research in hepatology and gastroenterology 8 35792239
2024 microRNA-15a-5p suppresses hypoxia-induced tumor growth and chemoresistance in bladder cancer by binding to eIF5A2. Neoplasma 7 38506035
2023 EIF5A2 specifically regulates the transcription of aging-related genes in human neuroblastoma cells. BMC geriatrics 7 36750933
2017 N1-guanyl-1,7-diaminoheptane enhances the chemosensitivity of acute lymphoblastic leukemia cells to vincristine through inhibition of eif5a-2 activation. Anti-cancer drugs 7 28885268
2025 Unveiling EIF5A2: A multifaceted player in cellular regulation, tumorigenesis and drug resistance. European journal of pharmacology 5 40194645
2023 New K50R mutant mouse models reveal impaired hypusination of eif5a2 with alterations in cell metabolite landscape. Biology open 5 36848144
2023 MicroRNA-577/EIF5A2 axis suppressed the proliferation of DDP-resistant nasopharyngeal carcinoma cells by blocking TGF-β signaling pathway. Chemical biology & drug design 5 37500510
2022 LINC00518 affects the proliferation, invasion and migration of cutaneous malignant melanoma cells via miR-526b-3p/EIF5A2 axis. Acta biochimica Polonica 5 35189053
2019 MicroRNA-588 regulates migration capacity and invasiveness of renal cancer cells by targeting EIF5A2. European review for medical and pharmacological sciences 5 31841179
2016 Identification and validation of AIB1 and EIF5A2 for noninvasive detection of bladder cancer in urine samples. Oncotarget 5 27203388
2025 Jiawei Danxuan Koukang and its key component Quercetin intervened in OSF carcinogenesis by inhibiting the AR/eIF5A2 signaling pathway-mediated EMT. Archives of oral biology 4 39961149
2025 Polyamines stimulate the protein synthesis of the translation initiation factor eIF5A2, participating in mRNA decoding, distinct from eIF5A1. The Journal of biological chemistry 4 40617352
2024 Long non-coding RNA RAD51-AS1 promotes the tumorigenesis of ovarian cancer by elevating EIF5A2 expression. Journal of cancer research and clinical oncology 4 38584230
2022 EIF5A2 Is Involved in the Biological Process of Cervical Cancer Cells through AGR2. Pharmacology 4 35640539
2023 Targeting eIF5A2 reduces invasion and reverses chemoresistance in SCC-9 cells in vitro. Histology and histopathology 1 37334930
2023 MiR-5189-3p Suppresses cell Proliferation, Invasion and Migration Through Targeting EIF5A2 in Laryngeal Squamous Cell Carcinoma. Biochemical genetics 1 37656330
2026 Epigenetic silencing and pharmacological inhibition of EIF5A2 foster venetoclax sensitivity in acute myeloid leukaemia. British journal of haematology 0 41606290
2026 Identification of Inhibitors for eIF5A2-Dependent Translation Elongation by Monitoring the Translational Efficiency of Polyproline Motif in Mitochondrial Fission Regulator 1. Biological & pharmaceutical bulletin 0 41730614
2026 The lncRNA OTX2-AS1 promotes NSCLC progression via the miR-377-5p/EIF5A2 axis and EMT induction. World journal of surgical oncology 0 41965714
2024 Tripartite Motif Containing 71 Suppresses Tumor Growth by Down-Regulating eIF5A2 Expression in Laryngeal Squamous Cell Carcinoma. Applied biochemistry and biotechnology 0 39579322

Missed literature

Know a paper Affinage missed for EIF5A2? Flag it for the maintainers and the community.

No submissions yet.